Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28632465 | 0.83 | CARM1 (0.42) | ABHD6HSD17B3CARM1AKR1C3ASIC3 | |
| SCHEMBL969282 | 0.76 | MAOA (0.52) | — | |
| SCHEMBL1530957 | 0.73 | CARM1 (0.44) | ABHD6HSD17B3CARM1AKR1C3ASIC3 | |
| SCHEMBL586327 | 0.73 | MAOA (0.59) | HSD17B3CARM1ASIC3 | |
| SCHEMBL1530624 | 0.72 | ABHD6 (0.44) | ABHD6HSD17B3CARM1AKR1C3ASIC3 | |
| SCHEMBL1300634 | 0.72 | PDE4D (0.53) | ABHD6HSD17B3CARM1AKR1C3ASIC3 | |
| SCHEMBL38665856 | 0.71 | AKR1C3 (0.55) | ABHD6HSD17B3CARM1AKR1C3ACACB | |
| SCHEMBL22504152 | 0.71 | AKR1C3 (0.55) | ABHD6HSD17B3CARM1AKR1C3ASIC3 | |
| SCHEMBL587507 | 0.71 | ABHD6 (0.59) | ABHD6HSD17B3CARM1AKR1C3 | |
| SCHEMBL15910999 | 0.71 | CTSL (0.40) | ABHD6HSD17B3CARM1ASIC3PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318355-B1 | 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2018-09-12 | — | — | EP | disclosed |
| US-8309597-B2 | 1,1′-diadamantyl carboxylic acids, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20110269736-A1 | 1,1'-Diadamantyl carboxylic acids, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269736-A1 | 1,1'-Diadamantyl carboxylic acids, medicaments containing such compounds and their use | HSD11B1, HSD17B1, HSD3B1 | ABHD6 804/4885HSD17B3 9/4885CARM1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.